reason report
bottom line lower forecast amgen
neulasta increas forecast mylan fulphila neulasta
biosimilar base updat launch trajectori fulphila
updat coheru recent receiv fda approv
neulasta biosimilar udenyca price target
lower reiter market perform
rate price target increas
reiter outperform rate threat biosimilar neulasta
final materi revenu eros neulasta
revenu contribut fulphila impact top bottom line
respect udenyca set come market
begin next year second neulasta biosimilar
complic market dynam price market
strategi believ entri anoth biosimilar neulasta like
trigger price reduct neulasta fulphila
price competit could get even intens spectrum
sandoz launch respect product
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
complet novemb edt distribut novemb edta descript
benchmark avail contact leerink partner publish depart
fulphila launch outperform expect manag disclos
earn call compani sell unit per week recent translat
quarterli run rate assum asp addit fulphila reach market
share pre-fil syring segment neulasta sale per accord
pegfilgrastim market mean quarterli
run rate howev estim fulphila sale back-load
lower number suggest given practic administr pharmaci
director interview middl comment initi
switch fulphila nonetheless fulphila revenu seem track reach almost
launch trajectori exceed prior forecast mylan
manag comment launch line plan surgic launch
focus commun oncolog clinic well hospital-bas outpati clinic regard
suppli capac manag state compani capac consist plan
affect suppli limit
udenyca price par fulphila coheru announc earn call last
thursday udenyca initi price per dose fulphila launch price
compani emphas price lower neulasta list price
lower neulasta averag sell price asp although publish
asp neulasta disclosur earn call indic
neulasta experienc price declin qoq global assum major price
eros happen us net price neulasta could
discount two biosimilar wac basi would appear less compel interestingli
coheru suggest earn call comprehens contract strategi
go roll gpo custom probabl next week remain
unclear net price udenyca undercut neulasta refer
anecdot net price fulphila interview practic administr
pharmaci director back see previou note
coheru emphas advantag suppli servic discuss
recent note follow udenyca approv link coheru believ major strength
greater manufactur capac arguabl better qualiti assist program
physician patient howev leav door open potenti price competit
read line comment overal continu believ econom
import factor drive switch brand neulasta shift share
udenyca launch januari expect coheru announc udenyca
avail us start januari reason decis consist
previou expect benefit delay launch next year three-fold
first coheru expect issu uniqu code udenyca januari
facilit reimburs medicar patient second coheru also want take advantag
typic time formulari reset payer januari udenyca could experi
littl reimburs gap possibl third small delay allow coheru time
prepar manufactur distribut udenyca build awar among
provid patient
acceler assumpt price share eros neulasta pt
although immedi clear big gap net price neulasta
udenyca next januari appear taken proactiv step lower net price
neulasta fulphila launch think move suggest will
defend neulasta franchis price competit unlik case
brand neupogen asp flat sinc launch granix therefor chang
assumpt model reflect aggress price reduct part
also acceler estim switch volum neulasta biosimilar particularli
segment small physician-own practic hospit given strong launch
fulphila model yoy neulasta revenu eros
per year thereaft forecast neulasta us sale lower
lower year revenu estim slightli recent
consensu consensu consensu
result non-gaap ep forecast come
ep forecast remain consensu price target
lower reiter market perform rate
increas near-term estim fulphila ep pt base
acceler estim volum switch neulasta biosimilar rais fulphila
sale estim continu appli risk-adjust
reflect risk limit suppli increas fulphila number rais
ep prev increas price target
prev fulphila revenu go rais ep
prev estim essenti unchang
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
million
corp partner revenue incl royalti
po probabl success fda approv
leerink partner research compani file
million
sale
total expens exclud revenue sharing/incl sg
 total revenu
sg total revenu excl profit share
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method model larg cap healthcar growth stock ep multipl
ep appli amgen ep
leerink updat ep estim
current averag ep multipl consensu ep
compar slow grow us eu larg cap biopharma
impli target price ep
revenu multipl appli leerink revenu forecast
leerink updat revenu estim
current averag larg cap biopharma multipl revenu
impli valu fy revenu
impli target price ep use us pharma compar
method dcf adjust debt declin flow
stabl termin cash flow growth discount
present valu flow termin valu
averag method
leerink partner research compani file factset
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
herceptin approv launch
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
price target inc stock rate market perform
one first gener pioneer biopharmaceut industri
succeed basi build three massiv revenu pillar legaci product
enbrel face array brand gener competitor mean
associ revenu total like steadili declin offset outlook
number recent develop acquir product growth
profit potenti view unlik match legaci brand least mani
year manag respond challeng restructur compani
expens base initi dividend lever compani balanc sheet cash
trap off-shore gener make legaci product compar peer
regard defens stock also one lack explos upsid potenti
typic associ breakthrough rapidli grow biotherapeut stock
price target inc base averag three approach
believ reason basi valu stock today approach simpl price
earn multipl larg cap us eu larg cap biopharma stock sni
rhhbi gsk nv price sale multipl larg cap biotechnolog pharma
compani novo discount cash flow dcf use rel multipl
larg cap biopharma compani ep appli ep
estim give one year futur valu use establish larg cap
futur revenu multipl sale appli revenu forecast amgen
give futur valu final dcf valuat base current
outlook compani exist product probability-weight revenu contribut
late stage pipelin program discount compani wacc give
fair valu today averag three approach give price target
risk view outlook valuat includ major chang label
price reimburs coverag compani legaci product failur
compani growth portfolio achiev futur sale forecast risk includ develop
delay disappoint earlier stage pipelin asset earlier signific eros
compani legaci product biosimilar innov competit shortfal
compani effort improv oper margin would also materi affect outlook
valuat would larg dilut acquisit therapeut area platform
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver
could expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair may get approv commerci uptak biosimilar may take longer
anticip growth ou market may slower expect market penetr
gener copaxon may improv biosimilar neulasta may slower estim
